Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Background Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor, or statin, that has been developed for the treatment of dyslipidemia.Objective This study assessed the metabolism, excretion, and pharmacokinetics of a single oral dose of radiolabeled rosuvastatin ([14C]-rosuvastatin) in healthy volunteers.Methods This was a nonrandomized, open-label, single-day trial. Healthy adult male volunteers were given a single oral dose of [14C]-rosuvastatin 20 mg (20 mL [14C]-rosuvastatin solution, nominally containing 50 microCi radioactivity). Blood, urine, and fecal samples were collected up to 10 days after dosing. Tolerability assessments were made up to 10 days after dosing (trial completion) and at a follow-up visit within 14 days of trial completion.Results Six white male volunteers aged 36 to 52 years (mean, 43.7 years) participated in the trial. The geometric mean peak plasma concentration (C(max)) of rosuvastatin was 6.06 ng/mL and was reached at a median of 5 hours after dosing. At C(max), rosuvastatin accounted for approximately 50% of the circulating radioactive material. Approximately 90% of the rosuvastatin dose was recovered in feces, with the remainder recovered in urine. The majority of the dose (approximately 70%) was recovered within 72 hours after dosing; excretion was complete by 10 days after dosing. Metabolite profiles in feces indicated that rosuvastatin was excreted largely unchanged (76.8% of the dose). Two metabolites-rosuvastatin-5S-lactone and N-desmethyl rosuvastatin-were present in excreta. [14C]-rosuvastatin was well tolerated; 2 volunteers reported 4 mild adverse events that resolved without treatment.Conclusions The majority of the rosuvastatin dose was excreted unchanged. Given the absolute bioavailability (20%) and estimated absorption (approximately 50%) of rosuvastatin, this finding suggests that metabolism is a minor route of clearance for this agent.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rosuvastatin provides a complementary example, with OATP1B1-mediated hepatic uptake governing systemic exposure and accounting for the marked increases in exposure observed in carriers of reduced-function SLCO1B1 polymorphisms [44].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [44]
In the citing paper
“The case is now a canonical example of why ECCS classification, transporter-DDI screening, and post-marketing pharmacoepidemiology must be integrated alongside any allometric or PBPK extrapolation [41,43,44,79].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [44]
In the citing paper
“The case directly catalyzed contemporary requirements for thorough QT studies and hERG screening, the metabolite-aware DDI evaluations that ECCS classification now anchors [41,43,44], and the broader regulatory expectation that compounds with active metabolites or saturable first-pass pathways be characterized across realistic co-medication scenarios rather than in isolation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [44]
Citations
Cites
Jones, P. H., Davidson, M. H., Stein, E. A., Bays, H. E., McKenney, J. M., Miller, E., Cain, V. A., & Blasetto, J. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00530-7 · Cited by 1,398
Rosuvastatin: A Highly Effective New HMG‐CoA Reductase Inhibitor
Olsson, A. G., McTaggart, F., & Raza, A. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00099.x · Cited by 204
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
Martin, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80316-8 · Cited by 191
Self-citationOlsson, A. G., Istad, H., Luurila, O., Ose, L., Stender, S., Tuomilehto, J., Wiklund, O., Southworth, H., Pears, J., & Wilpshaar, J. W. (2002) · American Heart Journal · doi:10.1067/mhj.2002.128049 · Cited by 177
Brown, W. V., Bays, H. E., Hassman, D. R., McKenney, J. M., Chitra, R., Hutchinson, H. G., & Miller, E. (2002) · American Heart Journal · doi:10.1067/mhj.2002.129312 · Cited by 156
Martin, P. D., Mitchell, P. D., & Schneck, D. W. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01688.x · Cited by 148
Self-citationBlasetto, J. W., Stein, E. A., Brown, W. V., Chitra, R., & Raza, A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00003-1 · Cited by 144
Effect of itraconazole on the pharmacokinetics of rosuvastatin
Cooper, K. D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(02)17633-8 · Cited by 115
The effect of fluconazole on the pharmacokinetics of rosuvastatin
Cooper, K., Martin, P. D., Dane, A. L., Warwick, M. J., Schneck, D. W., & Cantarini, M. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0508-8 · Cited by 113
Self-citationLiver-Specific Distribution of Rosuvastatin in Rats: Comparison with Pravastatin and Simvastatin
Nezasa, K.-I., Higaki, K., Matsumura, T., Inazawa, K., Hasegawa, H., Nakano, M., & Koike, M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1158 · Cited by 106
Research works printed but not linked: 1
- McCormick, 2000, ZD4522—an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems, J Clin Pharmacol, 40, 1055
Cited by
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
LEE, E., RYAN, S., BIRMINGHAM, B., ZALIKOWSKI, J., MARCH, R., AMBROSE, H., MOORE, R., LEE, C., CHEN, Y., & SCHNECK, D. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 480
“N-desmethyl rosuvastatin ormation is thought to occur primarily in the liver via ytochrome P450 2C9.(5) The lactone may also be ormed in the liver.”
BackgroundDifferent Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin
Pasanen, M. K., Fredrikson, H., Neuvonen, P. J., & Niemi, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100220 · Cited by 432
“Metabolism is not a major mechanism for rosuvastatin elimination, in which CYP2C9-mediated Ndemethylation and uridine diphosphate-glucuronosyltransferase 1A1- and uridine diphosphate-glucuronosyltransferase 1A3-mediated acyl-glucuronidation, followed by spontaneous lactonization, are minor pathways.(20,34,35) Cyclospo…”
BackgroundSIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
“16 Metabolic transformation plays a minor role in rosuvastatin clearance (CYP2C9 is the principal CYP isozyme involved in the limited metabolism of rosuvastatin), and thus the potential for clinically relevant metabolically mediated drug-drug interactions is low”
Background
Metadata
- Authors
- Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Martin, Paul D.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-11
- Volume
- 25
- Issue
- 11
- Pages
- 2822-2835
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2022507089
- Cited by
- 286
- References
- 20
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 11 · 2021: 13 · 2020: 15 · 2019: 12 · 2018: 19 · 2017: 9 · 2016: 14 · 2015: 23 · 2014: 16 · 2013: 20 · 2012: 13
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Clinical Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cell Science Research Foundation
- Shionogi
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- rosuvastatin, pharmacokinetics, drug metabolism, excretion, radiolabeled drug, statins, fecal excretion, urinary excretion, absolute bioavailability, tolerability
- MeSH terms
- Rosuvastatin Calcium, Adult, Biological Availability, Carbon Isotopes, Chromatography, High Pressure Liquid, Fluorobenzenes, Half-Life, Humans, Male, Metabolic Clearance Rate, Middle Aged, Pyrimidines, Sulfonamides, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. https://app.cochat.ai/papers/10.1016/s0149-2918(03)80336-3
- The paper
- Martin, P. D., Warwick, M. J., Dane, A. L., Hill, S. J., Giles, P. B., Phillips, P. J., & Lenz, E. (2003). Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clinical Therapeutics. https://doi.org/10.1016/s0149-2918(03)80336-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.